Implantable cardiac defibrillators in octogenarians

Maarten Pauwelyn; Sebastian Ingelaere; Ruben Hoffmann; Johan Vijgen; Georges H. Mairesse; Ivan Blankoff; Yves Vandekerckhove; Jean-Benoit le Polain de Waroux; Bert Vandenberk; Rik Willems

doi:10.26599/1671-5411.2023.01.007

Volume 20 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2023 > 20(1): 23-31

Please cite this article as: Pauwelyn M, Ingelaere S, Hoffmann R, Vijgen J, Mairesse GH, Blankoff I, Vandekerckhove Y, Waroux JBLPD, Vandenberk B, Willems R. Implantable cardiac defibrillators in octogenarians. J Geriatr Cardiol 2023; 20(1): 23−31. DOI: 10.26599/1671-5411.2023.01.007

Citation:

Please cite this article as: Pauwelyn M, Ingelaere S, Hoffmann R, Vijgen J, Mairesse GH, Blankoff I, Vandekerckhove Y, Waroux JBLPD, Vandenberk B, Willems R. Implantable cardiac defibrillators in octogenarians. J Geriatr Cardiol 2023; 20(1): 23−31. DOI: 10.26599/1671-5411.2023.01.007

Citation:

PDF( 716 KB)

Implantable cardiac defibrillators in octogenarians

doi: 10.26599/1671-5411.2023.01.007

1.
University Hospitals Leuven, Cardiology, Leuven, Belgium
2.
KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium
3.
UZA, Department of Cardiology, Antwerp, Belgium
4.
Jessa Ziekenhuis, Department of Cardiology, Hasselt, Belgium
5.
Cliniques du Sud Luxembourg, Department of Cardiology, Arlon, Belgium
6.
CHU Charleroi, Department of Cardiology, Charleroi, Belgium
7.
AZ Sint-Jan, Department of Cardiology, Brugge, Belgium
8.
University of Calgary, Libin Cardiovascular Institute, Calgary, Canada

RW is supported as postdoctoral clinical researcher by the Fund for Scientific Research-Flanders (FWO-Vlaanderen). RW reports research funding from Abbott, Biotronik, Boston Scientific, Medtronic; speakers and consultancy fees from Medtronic, Boston Scientific, Biotronik, Abbott.
^*The authors contributed equally to this manuscript

More Information

Corresponding author: vandenberkbert@gmail.com (Vandenberk B); rik.willems@uzleuven.be (Willems R)
Available Online: 2023-02-06
Publish Date: 2023-01-28

Abstract

Abstract

OBJECTIVE Implantable cardiac defibrillators (ICD) implantation in the very elderly remains controversial. We aimed to describe the experience and outcome of patients over 80 years old implanted with an ICD in Belgium. METHODS Data were extracted from the national QERMID-ICD registry. All implantations performed in octogenarians between February 2010 and March 2019 were analysed. Data on baseline patient characteristics, type of prevention, device configuration and all-cause mortality were available. To determine predictors of mortality, multivariable Cox proportional hazard regression modelling was performed. RESULTS Nationwide, 704 primo ICD implantations were performed in octogenarians (median age 82, IQR 81-83 years; 83% male and 45% secondary prevention). During a mean follow-up of 3.1 ± 2.3 years, 249 (35%) patients died, of which 76 (11%) within the first year after implantation. In multivariable Cox regression analysis age (HR = 1.15, P = 0.004), oncological history (HR = 2.43, P = 0.027) and secondary prevention (HR = 2.23, P = 0.001) were independently associated with 1-year mortality. A better preserved left ventricular ejection fraction (LVEF) was associated with a better outcome (HR = 0.97, P = 0.002). Regarding overall mortality multivariable analysis withheld age, history of atrial fibrillation, centre volume and oncological history as significant predictors. Higher LVEF was again protective (HR = 0.99, P = 0.008). CONCLUSIONS Primary ICD implantation in octogenarians is not often performed in Belgium. Among this population, 11% died within the first year after ICD implantation. Advanced age, oncological history, secondary prevention and a lower LVEF were associated with an increased one-year mortality. Age, low LVEF, atrial fibrillation, centre volume and oncological history were indicative of higher overall mortality.

FullText(HTML)

References(39)

References

[1]	Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933−1940. doi: 10.1056/NEJM199612263352601
[2]	Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882-1890. [Erratum, N Engl J Med 2000; 342: 1300].
[3]	Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877−883. doi: 10.1056/NEJMoa013474
[4]	Elming MB, Nielsen JC, Haarbo J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017; 136: 1772−1780. doi: 10.1161/CIRCULATIONAHA.117.028829
[5]	Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375: 1221−1230. doi: 10.1056/NEJMoa1608029
[6]	Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793−2867.
[7]	Santangeli P, Di Biase L, Russo AD, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010; 153: 592−599. doi: 10.7326/0003-4819-153-9-201011020-00009
[8]	Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8: 179−186. doi: 10.1161/CIRCOUTCOMES.114.001306
[9]	Huang DT, Sesselberg HW, Mcnitt S, et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007; 18: 833−838. doi: 10.1111/j.1540-8167.2007.00857.x
[10]	Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28: 1746−1749. doi: 10.1093/eurheartj/ehl438
[11]	Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients > or = 65 years of age. Am Heart J 2010; 160: 122−131. doi: 10.1016/j.ahj.2010.04.021
[12]	Barra S, Providência R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace 2015; 17: 174−186. doi: 10.1093/europace/euu296
[13]	Ageing and health. WHO. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health (accessed on April 19 2022).
[14]	Kramer DB, Matlock DD, Buxton AE, et al. (2015). Implantable cardioverter-defibrillator use in older adults: proceedings of a Hartford change AGEnts symposium. Circulation 2015; 8: 437−446.
[15]	Ruskin JN, Camm AJ, Zipes DP, et al. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002; 13: 38−43. doi: 10.1046/j.1540-8167.2002.00038.x
[16]	Kadish A, Dyer A, Daubert Quigg R, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151−2158. doi: 10.1056/NEJMoa033088
[17]	Bardy GH, Lee KL, Mark DB, et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225−237. doi: 10.1056/NEJMoa043399
[18]	Expósito V, Rodríguez-Mañero M, González-Enríquez S, et al. Primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator in elderly patients: results of a Spanish multicentre study. Europace 2016; 18: 1203−1210. doi: 10.1093/europace/euv337
[19]	Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. -Pacing Clin Electrophysiol 2012; 35: 131−134. doi: 10.1111/j.1540-8159.2011.03240.x
[20]	Suleiman M, Goldenberg I, Haim M, et al. Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defbrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD Registry. Heart Rhythm 2014; 11: 435−441. doi: 10.1016/j.hrthm.2013.12.003
[21]	Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005; 2: 907−911. doi: 10.1016/j.hrthm.2005.06.011
[22]	Yung D, Birnie D, Dorian P, et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation 2013; 127: 2383−2392. doi: 10.1161/CIRCULATIONAHA.113.001442
[23]	van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57: 556−562. doi: 10.1016/j.jacc.2010.06.059
[24]	AlTurki A, Proietti R, Alturki H, et al. Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: A meta-analysis. Hellenic J Cardiol 2019; 60: 276−281. doi: 10.1016/j.hjc.2017.12.003
[25]	Fudim M, Carlisle MA, Devaraj S, et al. One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. Eur J Heart Fail 2020; 22: 859−867. doi: 10.1002/ejhf.1755
[26]	van Rees JB, Borleffs CJ, Thijssen J, et al. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace 2012; 14: 66−73. doi: 10.1093/europace/eur255
[27]	Goonewardene M, Barra S, Heck P, et al. Cardioverter-defibrillator implantation and generator replacement in the octogenarian. Europace 2015; 17: 409−416. doi: 10.1093/europace/euu248
[28]	Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 288−296. doi: 10.1016/j.jacc.2007.08.058
[29]	Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012; 59: 2075−2079. doi: 10.1016/j.jacc.2012.02.036
[30]	Green AR, Leff B, Wang Y, et al. Geriatric conditions in patients undergoing defibrillator implantation for prevention of sudden cardiac death: prevalence and impact on mortality. Circ Cardiovasc Qual Outcomes 2016; 9: 23−30. doi: 10.1161/CIRCOUTCOMES.115.002053
[31]	Alba AC, Braga J, Gewarges M, et al. Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis. Can J Cardiol 2013; 29: 1729−1740. doi: 10.1016/j.cjca.2013.09.024
[32]	Koplan BA, Epstein LM, Albert CM, et al. Survival in octogenarians receiving implantable defibrillators. Am Heart J 2006; 152: 714−719. doi: 10.1016/j.ahj.2006.06.008
[33]	Ertel D, Phatak K, Makati K, et al. Predictors of early mortality in patients age 80 and older receiving implantable defibrillators. Pacing Clin Electrophysiol 2010; 33: 981−987.
[34]	Mezu U, Adelstein E, Jain S, Saba S. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death. Am J Cardiol 2011; 108: 718−722. doi: 10.1016/j.amjcard.2011.04.022
[35]	Kinch Westerdahl A, Sjöblom J, Mattiasson AC, et al. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation 2014; 129: 422−429. doi: 10.1161/CIRCULATIONAHA.113.002648
[36]	Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med 2004; 141: 835−838. doi: 10.7326/0003-4819-141-11-200412070-00006
[37]	Mitar M, Alba AC, MacIver J, Ross H. Lost in translation: examining patient and physician perceptions of implantable cardioverter-defibrillator deactivation discussions. Circ Heart Fail 2012; 5: 660−666. doi: 10.1161/CIRCHEARTFAILURE.112.967497
[38]	Verbrugge FH, Dupont M, De Vusser P, et al. Response to cardiac resynchronization therapy in elderly patients (≥ 70 years) and octogenarians. Eur J Heart Fail 2013; 15: 203−210. doi: 10.1093/eurjhf/hfs151
[39]	Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace 2022; 24: 71−164. doi: 10.1093/europace/euab232